-
Ik kreeg via mijn broker een verzoek om digitaal te stemmen op de punten voor de Aandeelhoudersvergadering.
Ik heb voor alle punten gestemd met uitzondering van punt 6 en punt 7b. Ik vind dat de directie van Pharming maar eens een keer een duidelijk signaal moet krijgen dat ze alles moeten financieren vanuit de cashflow die Pharming zelf genereert. Gewoon kappen met vragen om ruimte om aandelen uit te geven voor overnames. De lage bedragen waar ze om vragen koop je sowieso helemaal niets voor in biotech, dus het is gewoon onzin.
TEGEN:
Agenda item 6: Amendment to the Articles of Association and authorization to implement such amendment (voting item)
The articles of association of the Company (“Articles of Association”) provide in article 4 that the authorised capital amounts to eight million eight hundred thousand Euros (€8,800,000) and 880,000,000 shares with a nominal value of one Eurocent (€0,01) each). The Board of Directors proposes the General Meeting to amend the Articles of Association to the effect that the authorised capital is increased by 20% to ten million five hundred and sixty thousand Euros (€10,560,000 or 1,056,000,000 shares) with a nominal value of one Eurocent (€0,01) each, in consideration of the currently issued share capital (as per March 31, 2023), consisting of 658,672,343 shares of one Eurocent (€0.01) each, to facilitate the further growth of the Company and to increase the Company's flexibility in issuing new shares (subject to the authorization granted by the general meeting to the Board of Directors to issue shares from time to time).
In addition, it is proposed to authorize each civil law notary, candidate civil law notary and lawyer working with NautaDutilh N.V. to execute the deed of amendment to effect the amendments.
TEGEN:
7 b): specific authorization for financing of mergers, acquisitions or strategic alliances
The AGM is proposed to designate the Board of Directors, for a period of eighteen months starting on May 17, 2023, as the body authorized:
(i) to issue shares;
(ii) to grant rights to acquire shares; and
(iii) to limit or exclude pre-emptive rights;
limited to 10% of the issued share capital at the date of the AGM and to be used or the financing of mergers, acquisitions or strategic alliances only.
Acquiring or in-licensing new programs or companies that have assets that can be commercialized using Pharming’s in-house sales and marketing infrastructure is one of the three pillars in our strategy. Therefore, the proposed authority is required to provide the Board of Directors the required flexibility to respond timely and adequately to merger and/or acquisition or other strategic opportunities, in the best interest of the Company and all of its stakeholders.
The proposed authorization under this agenda item 7 b) will replace the current specific authorization for the financing of mergers, acquisitions or strategic alliances as granted by the General Meeting on May 18, 2022.
Any issue of or grant of rights to acquire shares in excess of the proposed authorizations under agenda items 7a) and 7b) will require a resolution or authorization of the General Meeting of Shareholders.
-